(Q66047046)

English

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

A Phase II Investigator Sponsored Multi-Centre Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma (English)

0 references

0 references

0 references

8 July 2016

0 references

end time

January 2020

0 references

number of participants

21

0 references

clinical trial phase

phase II clinical trial

0 references

research site

Samsung Medical Center

0 references

Singapore General Hospital

0 references

minimum age

21 year

0 references

maximum age

99 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT03093831

0 references

(Q66047046)

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)